Insider & Cluster Buy Highlights – January 13, 2026
📅 Published: January 13, 2026 at 01:44 PM UTC
4 Cluster Buys1 Insider Purchases
On January 13, 2026, this newsletter featured 4 cluster buys and 1 insider purchase detected from SEC Form 4 filings.
📈 Daily Insider & Cluster Buy Highlights – January 13, 2026
Here are some of the most interesting insider and cluster buying signals from the last 7 days.
⚠️ For information purposes only.
This information is provided for informational purposes only and does not constitute investment advice, financial advice, trading advice, or any other type of advice. All investments carry risk, including the potential loss of principal. Past performance is not indicative of future results. You should consult with a qualified financial advisor, accountant, or other professional before making any investment decisions. The information contained in this newsletter is not intended to be a substitute for professional financial advice.
📊 About Fair Value:
The Fair Value shown for each company is calculated using a Levered Discounted Cash Flow (DCF) model. This method estimates the intrinsic value of a stock by projecting future cash flows and discounting them back to present value, accounting for the company's debt structure. A positive percentage difference indicates the stock may be undervalued relative to this model, while a negative percentage suggests it may be overvalued. Fair value calculations are estimates and should be considered alongside other factors.
🔥 Notable Cluster Buys (≥ $500,000)
Aktis Oncology, IncView Chart
Ticker: AKTS
$21.75
Current Price
52W: Low: $19.33 | High: $29.16
Participants: 3 insiders
Total Shares: 3,892,222
Total Value: $70,059,996
Timeframe: 0 days
Date Range: Jan 12, 2026 to Jan 12, 2026
👥 Participant Details:
Vida Ventures II, LLC
Date: Jan 12, 2026
22,545 shares
$405,810
@ $18.00/share
P&L: +20.8% (+$84,544)
Vida Ventures II, LLC
Date: Jan 12, 2026
812,455 shares
$14,624,190
@ $18.00/share
P&L: +20.8% (+$3,046,706)
Kim Helen Susan
Date: Jan 12, 2026
812,455 shares
$14,624,190
@ $18.00/share
P&L: +20.8% (+$3,046,706)
EcoR1 Capital, LLC
Director
Date: Jan 12, 2026
2,077,779 shares
$37,400,022
@ $18.00/share
P&L: +20.8% (+$7,791,671)
EcoR1 Capital, LLC
Director
Date: Jan 12, 2026
144,443 shares
$2,599,974
@ $18.00/share
P&L: +20.8% (+$541,661)
Kim Helen Susan
Date: Jan 12, 2026
22,545 shares
$405,810
@ $18.00/share
P&L: +20.8% (+$84,544)
📈 Average P&L: +20.8% (+2,085,833)
Current Price: $21.75
📊 Valuation & Analyst Info:
Avg Price Target: $4.92 (-77.4% vs current)
📰 Recent News (Last 7 Days):
GlobeNewsWire • Jan 13, 2026
BOSTON, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Aktis Oncology, Inc. (“Aktis”), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large pa...
GuruFocus • Jan 12, 2026
Guru Stock PicksJerome Dodson has made the following transactions:Reduce in ORLY by 3%Sold out in BLDRAdd in NTRA by 2.49%New position in INSMTweedy Browne Inte
Seeking Alpha • Jan 09, 2026
U.S. IPO Weekly Recap: Aktis Oncology Leads As First Sizable 2026 IPO
GuruFocus • Jan 09, 2026
Stock News California billionaire tax splits tech leaders: Nvidia (NVDA) CEO Jensen Huang said he's âfineâ with a proposed one-time 5% California wealth tax
GuruFocus • Jan 09, 2026
Aktis Oncology Inc. (AKTS) drew strong investor demand in its Nasdaq debut, with shares trading at $22.91 as of 12:19 p.m. Friday in New York after pricing its
Business Wire • Jan 09, 2026
LOS ANGELES & BOSTON--(BUSINESS WIRE)--Vida Ventures (“Vida”), a next-generation life sciences venture firm, today congratulates Aktis Oncology (Nasdaq: AKTS), a clinical-stage biotechnology company a...
Reuters • Jan 08, 2026
Cancer drug developer Aktis Oncology said on Thursday it priced its upsized U.S. initial public offering at $18 per share, raising about $318 million.
GlobeNewsWire • Jan 08, 2026
BOSTON, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Aktis Oncology, Inc. (“Aktis”), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large pa...
Seeking Alpha • Jan 06, 2026
Aktis Oncology, Inc. seeks $200 million in IPO funding to advance radiopharmaceutical candidates for solid tumor cancers. AKTS's lead asset [225Ac]Ac-AKY-1189 is in Phase 1b trials, with preliminary r...
ALUMIS INCView Chart
Ticker: ALMS
$21.09
Current Price
52W: Low: $2.76 | High: $22.30
$4.90
Fair Value
Participants: 3 insiders
Total Shares: 1,235,292
Total Value: $20,999,964
Timeframe: 0 days
Date Range: Jan 08, 2026 to Jan 08, 2026
👥 Participant Details:
Foresite Labs, LLC
10% Owner
Date: Jan 08, 2026
294,117 shares
$4,999,989
@ $17.00/share
P&L: +24.1% (+$1,202,939)
Tananbaum James B.
Director
Date: Jan 08, 2026
117,647 shares
$1,999,999
@ $17.00/share
P&L: +24.1% (+$481,176)
Tananbaum James B.
Director
Date: Jan 08, 2026
294,117 shares
$4,999,989
@ $17.00/share
P&L: +24.1% (+$1,202,939)
Foresite Capital Management VI LLC
10% Owner
Date: Jan 08, 2026
117,647 shares
$1,999,999
@ $17.00/share
P&L: +24.1% (+$481,176)
Foresite Capital Management VI LLC
10% Owner
Date: Jan 08, 2026
294,117 shares
$4,999,989
@ $17.00/share
P&L: +24.1% (+$1,202,939)
Foresite Labs, LLC
10% Owner
Date: Jan 08, 2026
117,647 shares
$1,999,999
@ $17.00/share
P&L: +24.1% (+$481,176)
📈 Average P&L: +24.1% (+842,057)
Current Price: $21.09
📊 Valuation & Analyst Info:
Fair Value: $4.90 (76.8% overvalued vs current price)
Analyst Rating: C+
Avg Price Target: $35.14 (+66.6% vs current)
📰 Recent News (Last 7 Days):
GlobeNewsWire • Jan 09, 2026
SOUTH SAN FRANCISCO, Calif., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing next-generation targeted therapies for patients with im...
GlobeNewsWire • Jan 07, 2026
SOUTH SAN FRANCISCO, Calif., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing next-generation targeted therapies for patients with im...
Zacks Investment Research • Jan 07, 2026
Alumis shares jump 95% after envudeucitinib meets all endpoints in two phase III plaque psoriasis studies, showing strong skin clearance.
Seeking Alpha • Jan 07, 2026
Alumis Inc. surged 95% after reporting strong Phase 3 results for lead candidate envudeucitinib in moderate-to-severe plaque psoriasis. Envudeucitinib demonstrated high efficacy for an oral agent, wit...
Defense World • Jan 07, 2026
Alumis (NASDAQ: ALMS) used a conference call to highlight positive top-line Phase III results for envudeucitinib, its next-generation oral TYK2 inhibitor, in adults with moderate to severe plaque psor...
The Motley Fool • Jan 06, 2026
Investors today are cheering envudeucitinib's Phase 3 edge in oral TYK2 psoriasis as well as Alumis' plans to raise fresh capital.
GlobeNewsWire • Jan 06, 2026
SOUTH SAN FRANCISCO, Calif., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing next-generation targeted therapies for patients with im...
Schaeffers Research • Jan 06, 2026
Biotech stock Alumis Inc (NASDAQ:ALMS) is skyrocketing today, up 107.9% at $17.28 at last glance, after the Johnson & Johnson (JNJ) rival announced its plaque psoriasis drug, envudeucitinib, met all o...
Benzinga • Jan 06, 2026
Alumis Inc. (NASDAQ: ALMS) stock is trading higher on Tuesday, with a session volume of 4.33 million compared to the average volume of 1.02 million as per data from Benzinga Pro.
Reuters • Jan 06, 2026
Alumis said on Tuesday its experimental pill met the main goal in two late-stage studies in patients with a type of skin disease.
GlobeNewsWire • Jan 06, 2026
– Both Phase 3 trials met all primary and secondary endpoints with high statistical significance in patients with moderate-to-severe plaque psoriasis – – Approximately 65% of patients achieved PASI 90...
Strategy IncView Chart
Ticker: MSTR
$162.23
Current Price
52W: Low: $149.75 | High: $457.22
Participants: 2 insiders
Total Shares: 5,012
Total Value: $780,595
Timeframe: 4 days
Date Range: Jan 08, 2026 to Jan 12, 2026
👥 Participant Details:
Le Phong
Date: Jan 08, 2026
12 shares
$1,200
@ $99.99/share
P&L: +62.2% (+$747)
RICKERTSEN CARL J
Date: Jan 12, 2026
5,000 shares
$779,395
@ $155.88/share
P&L: +4.1% (+$31,755)
📈 Average P&L: +33.2% (+16,251)
Current Price: $162.23
📊 Valuation & Analyst Info:
Analyst Rating: A-
Avg Price Target: $438.67 (+170.4% vs current)
📰 Recent News (Last 7 Days):
24/7 Wall Street • Jan 12, 2026
Do you like to walk on the wild side? Are you bullish on Bitcoin (CRYPTO:BTC)?
CNBC • Jan 11, 2026
Two Senate committees will hold hearings Thursday to work on their parts of a crypto market structure bill. The drafts will be merged to create one big bill, which will go to the Senate floor for a vo...
Fool - Investing News • Jan 11, 2026
Up to four potential bubbles are threatening to burst in the new year.
Benzinga • Jan 10, 2026
Retail investors talked up five hot stocks this week (Jan. 2 to Jan. 9) on X and Reddit's r/WallStreetBets: GME, NVDA, MSTR, GOOG, TSLA.
Defense World • Jan 10, 2026
Shares of Defiance Daily Target 1.75X Long MSTR ETF (NASDAQ: MSTX - Get Free Report) fell 11.4% during mid-day trading on Friday. The stock traded as low as $3.95 and last traded at $4.05. 63,132,748 ...
Zacks Investment Research • Jan 09, 2026
Strategy (MSTR) concluded the recent trading session at $157.33, signifying a -5.77% move from its prior day's close.
Zacks Investment Research • Jan 08, 2026
MSTR gets a lift after MSCI pauses plans to exclude digital-asset holders from indexes, easing a key near-term risk for the stock.
GuruFocus • Jan 08, 2026
Bitcoin (BTC-USD) moved back below the $90,000 threshold on Thursday as selling pressure resurfaced across digital assets, coinciding with a notable acceleratio
Schwab Network • Jan 07, 2026
While memory stocks largely pulled back on some of Tuesday's strength and analysts hit big banks with downgrades, Marley Kayden and Sam Vadas turn to wins elsewhere on Wall Street. Among them: Intel's...
CNBC Television • Jan 07, 2026
CNBC's MacKenzie Sigalos reports MSCI hit pause on a potential index boot for crypto-heavy companies like Strategy — lifting a key overhang for the digital-asset treasury trade even as ETFs make the c...
Investopedia • Jan 07, 2026
Strategy shareholders haven't caught many breaks lately. They did this week.
Investopedia • Jan 07, 2026
Major stock indexes were mixed Wednesday, with the Dow Jones Industrial Average and S&P 500 setting fresh all-time highs before the Dow turned lower.
Proactive Investors • Jan 07, 2026
Strategy Incorporated (NASDAQ:MSTR) shares rose more than 4% following news that American finance firm MSCI will, for now, maintain the company's inclusion in its major equity indexes. The move provid...
GuruFocus • Jan 07, 2026
Shares of Strategy (MSTR) climbed about 3% Wednesday morning after MSCI decided not to remove digital asset treasury (DAT) companies from its indexes during the
Zacks Investment Research • Jan 07, 2026
Recently, Zacks.com users have been paying close attention to Strategy (MSTR). This makes it worthwhile to examine what the stock has in store.
247 Wallst • Jan 07, 2026
Live Updates Huang's Nod to Musk 41 minutes ago Live Nvidia CEO Jensen Huang has given a nod to Elon Musk, reportedly calling Tesla's (Nasdaq: TSLA) autonomous vehicle stack is the "most advanced" on ...
247 Wallst • Jan 07, 2026
Live Updates Micron Could Test $400 a Share 1 hour ago Live Over the last few days, shares of Micron (NASDAQ: MU) raced about $43 higher. Yesterday alone, MU was up $31.28 a share, or 10%. Now, analys...
Schaeffers Research • Jan 07, 2026
Investors are unpacking private payrolls data for December this morning, with the Dow and S&P 500 indicating a muted open
Forbes • Jan 07, 2026
Strategy stock (MSTR) is making news once more after MSCI declared on January 6, 2026, that it will not remove digital asset treasury companies from its indexes. This choice was a significant relief f...
Barrons • Jan 07, 2026
It's rare for Strategy shares to rise when the large-cap cryptocurrency is falling.
Proactive Investors - Finance • Jan 07, 2026
Strategy Incorporated (NASDAQ:MSTR) shares rose more than 4% following news that American finance firm MSCI will, for now, maintain the company’s inclusion...
Benzinga • Jan 06, 2026
Global index provider MSCI decided against excluding cryptocurrency treasury companies from its Global Investable Market Indexes on Monday, significantly boosting shares of companies such as Strategy ...
Market Watch • Jan 06, 2026
Strategy gets to stay in MSCI indexes for now — though the index provider says it will launch a more general review of whether investment-oriented companies can keep their spots.
Zacks Investment Research • Jan 06, 2026
MSTR posts a $17.44B Q4 unrealized bitcoin loss as price swings hit results, pushing shares down 47.5% and prompting liquidity moves to manage volatility.
FXEmpire • Jan 06, 2026
Traders are paying close attention to the Bitcoin market, and whether or not it can recover to make decisions here.
TriplePoint Venture Growth BDC CorpView Chart
Ticker: TPVG
$6.56
Current Price
52W: Low: $5.24 | High: $8.20
Participants: 2 insiders
Total Shares: 95,420
Total Value: $619,544
Timeframe: 1 days
Date Range: Jan 07, 2026 to Jan 08, 2026
👥 Participant Details:
Srivastava Sajal
Director
Date: Jan 07, 2026
30,877 shares
$198,570
@ $6.43/share
P&L: +2.0% (+$3,983)
Labe James
Director
Date: Jan 07, 2026
30,877 shares
$198,570
@ $6.43/share
P&L: +2.0% (+$3,983)
Srivastava Sajal
Director
Date: Jan 08, 2026
16,833 shares
$111,202
@ $6.61/share
P&L: -0.7% ($778)
Labe James
Director
Date: Jan 08, 2026
16,833 shares
$111,202
@ $6.61/share
P&L: -0.7% ($778)
📈 Average P&L: +0.7% (+1,603)
Current Price: $6.56
📊 Valuation & Analyst Info:
Analyst Rating: B
Avg Price Target: $5.50 (-16.2% vs current)
📰 Recent News (Last 7 Days):
Defense World • Jan 11, 2026
TriplePoint Venture Growth BDC Corp. (NYSE: TPVG - Get Free Report) insider Sajal Srivastava acquired 30,877 shares of the business's stock in a transaction on Wednesday, January 7th. The stock was pu...
Defense World • Jan 11, 2026
TriplePoint Venture Growth BDC Corp. (NYSE: TPVG - Get Free Report) CEO James Labe acquired 30,877 shares of TriplePoint Venture Growth BDC stock in a transaction dated Wednesday, January 7th. The sto...
Seeking Alpha • Jan 07, 2026
TriplePoint Venture Growth (TPVG) trades at 0.74x book with a 14% yield, but a low 5.1% ROAA reveals a significant gap between portfolio yield and true economic returns. Unlike peers HTGC and TRIN, TP...
Defense World • Jan 06, 2026
TriplePoint Venture Growth BDC Corp. (NYSE: TPVG - Get Free Report) insider Sajal Srivastava purchased 27,153 shares of the company's stock in a transaction dated Friday, January 2nd. The shares were ...
TriplePoint Venture Growth BDC (NYSE:TPVG) Insider Sajal Srivastava Purchases 30,459 Shares of Stock
Defense World • Jan 06, 2026
TriplePoint Venture Growth BDC Corp. (NYSE: TPVG - Get Free Report) insider Sajal Srivastava acquired 30,459 shares of the business's stock in a transaction that occurred on Wednesday, December 31st. ...
Defense World • Jan 06, 2026
TriplePoint Venture Growth BDC Corp. (NYSE: TPVG - Get Free Report) CEO James Labe purchased 30,459 shares of the company's stock in a transaction on Wednesday, December 31st. The stock was bought at ...
Defense World • Jan 06, 2026
TriplePoint Venture Growth BDC Corp. (NYSE: TPVG - Get Free Report) CEO James Labe acquired 27,153 shares of the stock in a transaction on Friday, January 2nd. The shares were purchased at an average ...
💼 Notable Individual Insider Buys (≥ $100,000)
$4.10
Current Price
Transaction Date: Jan 09, 2026
Shares: 160,000
Purchase Price: $4.56
Purchase Value: $729,600
📉
P&L: 10.1% ($73,600 loss)
📊 Valuation & Analyst Info:
Analyst Rating: C+
This newsletter is generated automatically. Please verify all information independently before making investment decisions.
Want to receive these newsletters in your inbox? Sign up here